BioAtla, Inc. (BCAB) NASDAQ
3.53
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.53
+0(+0.00%)
Currency In USD
| Previous Close | 3.53 |
| Open | 3.61 |
| Day High | 3.65 |
| Day Low | 3.53 |
| 52-Week High | 71.5 |
| 52-Week Low | 3.26 |
| Volume | 21,992 |
| Average Volume | 38,484 |
| Market Cap | 4.45M |
| PE | -0.08 |
| EPS | -41.56 |
| Moving Average 50 Days | 5.1 |
| Moving Average 200 Days | 21.59 |
| Change | 0 |
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
GlobeNewswire Inc.
Mar 02, 2026 12:30 PM GMT
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
GlobeNewswire Inc.
Dec 31, 2025 12:00 PM GMT
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65% ownership of Oz-V across all solid
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
GlobeNewswire Inc.
Nov 21, 2025 5:25 AM GMT
These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to com